Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the treatment of type 2 diabetes due to their ability to reduce weight and attenuate hyperglycemia. However, the activity of glucagonlike peptide 1 receptor–directed strategies is submaximal, and the only potent, sustainable...

Descripción completa

Detalles Bibliográficos
Autores principales: Capozzi, Megan E, DiMarchi, Richard D, Tschöp, Matthias H, Finan, Brian, Campbell, Jonathan E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263842/
https://www.ncbi.nlm.nih.gov/pubmed/29905825
http://dx.doi.org/10.1210/er.2018-00117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263842/
https://www.ncbi.nlm.nih.gov/pubmed/29905825
http://dx.doi.org/10.1210/er.2018-00117

Ejemplares similares